PACAP and migraine.
other
Where this comes from
- Record sourced from PubMed, PMID 40442928.
- Also identified by DOI 10.1093/brain/awaf131.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A number of neuropeptides, including pituitary adenylate cyclase-activating polypeptide (PACAP), play an important role in the pathophysiology of migraine. Infusions of PACAP in patients with migraine can provoke migraine attacks. A placebo-controlled study with a monoclonal antibody directed against the PACAP-receptor failed to show efficacy. In a small, short, proof-of-concept study, a monoclonal antibody directed against PACAP (Lu AG09222) showed efficacy in reducing monthly migraine days compared to placebo but failed for the end point 50% reduction in migraine days. The ongoing PROCEED study, a double-blind, placebo-controlled, dose-finding study investigating four different doses of Lu AG09222 versus placebo for migraine prevention, is expected to complete in the second half of 2025.
Medical subject headings
- Migraine Disorders
- Pituitary Adenylate Cyclase-Activating Polypeptide